Australian prescription medicine decision summary...Ruxience (rituximab) was approved for the following therapeutic use...Chronic lymphocytic leukaemia...Ruxience is indicated for the treatment of patients with CD20 positive chronic lymphocytic leukaemia (CLL) in combination with chemotherapy.